PITTSBURGH, Pennsylvania —Lipella, an early-stage biotech company focusing on bladder-based ailments, is raising $1 million, according to a filing with the Securities and Exchange Commission.
Lipella is researching therapies for urinary bladder dysfunction, including treatments for overactive bladder, superficial bladder cancer and interstitial cystitis, which is also known as painful bladder syndrome.
The treatments are delivered into the bladder: a more direct delivery approach than many therapies that the company says will cut side effects and is often easily reimbursable.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Lipella’s lead product treats bladder irritation.
The four-year-old company has received seed level investments including from the Pittsburgh Life Sciences Greenhouse.